Ark Bio Of China Bets On Untapped Pediatric Antiviral Market Where Few Have Succeeded

Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.

Emerging Company Profile Regular column feature image Version 2

After Roche acquired Genentech Inc. and focused its attention largely on oncology drugs, Jim Wu, a US-trained biochemist who returned to China to work for Roche, saw opportunities in the Swiss drug maker's antiviral pipeline.

Wu who was a director at the Roche R&D center in Shanghai, founded a start-up in 2014, Ark Biosciences...

More from Anti-infective

More from Therapeutic Category